Jazz Pharmaceuticals plc — Director's Dealing 2015

Mar 2, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2015-02-26

Reporting Person: Tobias Jeffrey K (EVP, R&D & CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-02-26	Ordinary Shares	A	5755.0	$0.0	Acquired	40818	Direct
2015-02-27	Ordinary Shares	F	704.0	$170.09	Disposed	40114	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-02-26	Incentive Stock Option (right to buy)	$175.19	A	570.0	Acquired	2025-02-25	Ordinary Shares (570)	Direct
2015-02-26	Non-Qualified Stock Option (right to buy)	$175.19	A	14430.0	Acquired	2025-02-25	Ordinary Shares (14430)	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in four equal annual installments on the anniversary of the grant date, February 26, 2015.

F2: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F3: These two options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these two options vest over four years measured from the grant date, February 26, 2015, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.